Hyderabad, May 7: Project Serotonin (www.projectserotonin.com), a pioneering next-generation preventive healthtech company, today announced the launch of its first specialised protocol, the Gut Health Protocol, developed on its eighth-generation scalable AI/ML-enabled precision health platform. Smiles Institute of Gastroenterology, Bengaluru, one of India’s leading centres for gastroenterology and digestive sciences, will deploy the Protocol across its patient care pathways under the clinical stewardship of Dr CM Parameshwara, a renowned practitioner in the field.
The Gut Health Protocol is the first in a planned series of specialised protocols that will extend Project Serotonin’s precision platform into specific health domains to function as therapy adjuncts. These protocols, unique to the Platform, are built using first principles and genetics-first, whole system approaches. All variables are considered, including genetics, blood and urine biomarkers, diet, age, gender and lifestyle that may affect related health outcomes. These highly precise and personalized protocols follow rigorous, real-world pilots for efficacy and usability before release. Further, these are continuously optimized for every user journey, and have outcomes that are measurable and trackable longitudinally.
Project Serotonin’s Gut Health Protocol identifies an individual’s inherited predispositions to digestive conditions, then validates and contextualizes them through biomarker data. This integrated view enables personalized interventions, e.g. foods to avoid or include, supplements that must be added to the diet to address underlying biological drivers rather than symptoms alone. Recommendations are continuously refined as new data is collected, functioning as a precision therapy adjunct alongside clinical care.
Explaining the approach adopted by Project Serotonin’s Gut Health Protocol, Dr Ashwat Visvanathan (PhD), Head – Partnerships and User Outcomes, Project Serotonin said.
“Our proprietary genetic models decode how your body is fundamentally wired, enabling us to correct gut-related issues through highly precise, personalized interventions across diet, supplements, and lifestyle. Smiles Institute of Gastroenterology’s decision to deploy the platform across its patient care pathways reflects a growing recognition among leading clinical institutions that precision foundational health when integrated into the treatment journey can meaningfully improve patient experience and long-term outcomes.”
Speaking on the association with Project Serotonin, Dr CM Parameshwara, CEO & Founder, Smiles Institute of Gastroenterology said,
“What drew us to Project Serotonin’s platform is the rigour of their approach starting from genetic predisposition, validating through biomarkers, and building corrective strategies that complement the clinical interventions we provide. Deploying this within our patient care pathways allows us, for the first time, to offer a precision, data-driven layer of foundational health optimisation that works alongside treatment and meaningfully improves the patient journey. By deploying Project Serotonin’s platform, we have gained access to a first-of-its-kind precision health infrastructure that has been built and refined over a decade.”
Despite growing prevalence of significant genetic predispositions for gut related conditions around the world, most approaches to gut health remain reactive, treating symptoms after they manifest rather than addressing biological root causes. Imbalances in the gut have been known to have significant downstream effects affecting mental health, thyroid health, skin and hair health and immune health. Moreover, there is a significant overlap of symptoms across different gut health conditions, making the diagnosis of these conditions even more complicated.
